Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.

Annals of surgical oncology - 1 Dec 2013

An Ho Jung, Ryu Min-Hee, Ryoo Baek-Yeol, Sohn Byeong Seok, Kim Ki-Hun, Oh Sung Tae, Yu Chang Sik, Yook Jeong Hwan, Kim Byung Sik, Kang Yoon-Koo

Abstract excerpt

BACKGROUND: Baseline tumor size is one of important prognostic factors for imatinib therapy in patients with advanced gastrointestinal stromal tumor (GIST). The purpose of this study was to determine whether surgical cytoreduction before imatinib therapy can improve the prognosis. METHODS: A total of 249 patients with advanced GIST were reviewed retrospectively. Patients were categorized into two groups according...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Peritoneal Neoplasms

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 24052319
DOI: 10.1245/s10434-013-3279-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.PMID 24052319Read ↗

Metastasectomy for gastrointestinal stromal tumors.Semantic proximity Read ↗

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Semantic proximity Read ↗

Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.Semantic proximity Read ↗

Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.Semantic proximity Read ↗

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.Semantic proximity Read ↗

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.Semantic proximity Read ↗

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).Semantic proximity Read ↗

Management of gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.